TI
AIMT

Trexquant Investment’s Aimmune Therapeutics AIMT Stock Holding History

Trexquant Investment’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-13,953
Closed -$201K – 1607
2020
Q1 		$201K Buy
+13,953
New +$357K 0.01% 976
2019
Q2 		– Sell
-16,593
Closed -$371K – 1275
2019
Q1 		$371K Buy
+16,593
New +$391K 0.03% 675
2018
Q2 		– Sell
-32,755
Closed -$1.04M – 1371
2018
Q1 		$1.04M Buy
32,755
+27,047
+474% +$952K 0.07% 398
2017
Q4 		$216K Buy
+5,708
New +$184K 0.02% 903

Other funds holding AIMT

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Trexquant Investment's AIMT Position: Q2 2020 in Review

Trexquant Investment sold out of Aimmune Therapeutics (AIMT) in Q2 2020, closing a stake of 13,953 shares — an estimated $201K sold.

Trexquant Investment first reported a position in AIMT in Q4 2017 and held it in 4 quarters. The position peaked at $1.04M in Q1 2018. 165 funds tracked by Wall St. Rank hold AIMT as of Q2 2020.

  • Trexquant Investment reported no remaining Aimmune Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Trexquant Investment sold 13,953 Aimmune Therapeutics shares in Q2 2020, an estimated $201K.
  • Trexquant Investment first reported a position in Aimmune Therapeutics in Q4 2017 and held it in 4 quarters.
  • Trexquant Investment's Aimmune Therapeutics position peaked at $1.04M in Q1 2018.
  • 165 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q2 2020.

Based on Trexquant Investment's 13F filing for Q2 2020, filed 7 Aug 2020.